{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sitravatinib", "query": { "intervention": "sitravatinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sitravatinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T22:31:33.211Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Ureter", "Urothelial Carcinoma of the Renal Pelvis and Ureter", "Urothelial Carcinoma Urethra" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2018-09-11", "completion_date": "2022-08-22", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 36, "location_summary": "Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606174" }, { "nct_id": "NCT04904302", "title": "Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sitravatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-05-03", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Houston, Texas", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04904302" }, { "nct_id": "NCT04164199", "title": "Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Pamiparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "BAT1706", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "BGB-15025", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "BGB-A445", "type": "DRUG" }, { "name": "Surzebiclimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "LBL-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2019-12-19", "completion_date": "2026-05-23", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 4, "location_summary": "Miami, Florida • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164199" }, { "nct_id": "NCT04887870", "title": "Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced or Metastatic Solid Malignancies" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab Vedotin-Ejfv", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2021-06-29", "completion_date": "2025-09-25", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 13, "location_summary": "Littleton, Colorado • Goshen, Indiana • Boston, Massachusetts + 10 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887870" }, { "nct_id": "NCT03015740", "title": "Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Kidney Carcinoma", "Stage III Renal Cell Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sitravatinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2017-04-23", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015740" }, { "nct_id": "NCT04123704", "title": "Sitravatinib in Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Stage IV", "Triple Negative Breast Cancer", "Breast Neoplasms", "Breast Cancer Metastatic" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xiang Zhang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-09-22", "completion_date": "2023-01-22", "has_results": true, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04123704" }, { "nct_id": "NCT02954991", "title": "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Glesatinib", "type": "DRUG" }, { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Mocetinostat", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2016-11-07", "completion_date": "2021-11-04", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 25, "location_summary": "Yuma, Arizona • Beverly Hills, California • Duarte, California + 21 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954991" }, { "nct_id": "NCT02219711", "title": "Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "MGCD516", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2014-08", "completion_date": "2022-04-27", "has_results": false, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 37, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219711" }, { "nct_id": "NCT04518046", "title": "Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear-Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-08-11", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518046" }, { "nct_id": "NCT04800614", "title": "A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adults" ], "interventions": [ { "name": "sitravatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2021-03-15", "completion_date": "2022-03-28", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-09-12T22:31:33.211Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800614" } ] }